Stage-specific embryogenic antigen-4 expression in castration-resistant prostate cancer and its correlation with the androgen receptor

Junki Harada, Yasuyoshi Miyata, Takenobu Taima, Tsuyoshi Matsuda, Yuta Mukae, Kensuke Mitsunari, Tomohiro Matsuo, Kojiro Ohba, Tetsuji Suda, Hideki Sakai, Akihiro Ito, Seiichi Saito

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aim: Stage-specific embryonic antigen (SSEA)-4 plays important roles in the malignant aggressiveness of various cancers. The aim of this study was to investigate the pathological characteristics of SSEA-4 in castration-resistant prostate cancer (CRPC). Materials and Methods: SSEA-4 expression and its pathological roles were evaluated in five prostate cancer (PC) cell lines and 27 CRPC tissues. The relationship between SSEA-4 and the androgen receptor (AR) was also examined. Results: SSEA4 expression was detected in AR-negative cells (PC3, DU145, and AICaP1) but was not detected in AR-positive cells (LNCaP and AICaP2). SSEA-4 expression in human CRPC tissues was significantly higher than that in locally advanced or metastatic hormone sensitive PC (HSPC) tissues. A negative correlation was also detected between SSEA-4 and AR in CRPC tissues but not in HSPC tissues. Conclusion: SSEA-4 was over-expressed in CRPC and the changes were mediated by complex mechanisms that related to the AR and hormonal therapy.

Original languageEnglish
Pages (from-to)3327-3335
Number of pages9
JournalAnticancer research
Volume41
Issue number7
DOIs
Publication statusPublished - 2021 Jul
Externally publishedYes

Keywords

  • Androgen receptor (AR)
  • Castrationresistant prostate cancer (CRPC)
  • Hormonal therapy
  • Stage-specific embryonic antigen (SSEA)-4

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Stage-specific embryogenic antigen-4 expression in castration-resistant prostate cancer and its correlation with the androgen receptor'. Together they form a unique fingerprint.

Cite this